Carboplatin and cisplatin combined with etopside in patients with advanced non-small-cell lung cancer
- VernacularTitle:卡铂、顺铂和依托泊苷联合方案治疗23例晚期非小细胞肺癌
- Author:
Hua JIANG
;
Hongxing ZHANG
;
Weimei JIANG
- Publication Type:Journal Article
- Keywords:
non-small-cell lung;
carboplatin;
cisplatin combined chemotherapy
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the effect, tolerabilily and toxic-side reactions of combined carboplatin and cisplatin with etopside in advanced non-small-cell lung cancer.Methods:From Oct. 1998 to Mar. 2000, 23 cases with advanced non-small-cell lung cancer were treated by combined carboplatin [200 mg/m 2intravenously (IV) on day 1]and Cisplatin ( 30 mg/m 2 IV on day 3～5) and etopside (100mg/m 2 IV on day 1～5) . The treatment was repeated every 3～4 weeks.Results:86 cycles were completed in the whole group. Median cycles was 4. The overall response rate was 43.48%(10/23,PR), the median survival time was 8.2 months, the 1-year survival rate was 32%. Myelosuppression was the main toxicity, The overall response rate was 86.96%(20/23). Conclusions:Our results indicate that combined carboplatin and cisplatin with etopside regimen is effective for advanced non-small-cell lung cancer.
